IPP Bureau
Lupin to present Phase 1 Data on STING agonist at the ESMO Congress 2025
By IPP Bureau - October 13, 2025
The presentation will provide qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with solid tumors
Bristol Myers Squibb buys Orbital Therapeutics for $1.5 billion to strengthen cell therapy portfolio
By IPP Bureau - October 12, 2025
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
Samsung Biologics introduces optimized manufacturing framework ‘ExellenS’
By IPP Bureau - October 12, 2025
ExellenS applies optimized facility designs, equipment, and processes across all sites to ensure equivalency and speed
AstraZeneca to lower cost of medicines for American patients
By IPP Bureau - October 12, 2025
AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing
Novo Nordisk to acquire Akero Therapeutics for $5.2 billion
By IPP Bureau - October 12, 2025
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
Merck unveils new HIV treatment and prevention data at EACS 2025
By IPP Bureau - October 12, 2025
Merck will showcase results in innovative solutions in HIV treatment and prevention
FDA approves Teva’s expanded indication for Uzedy for bipolar I disorder
By IPP Bureau - October 11, 2025
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
Merck advances cancer innovation by expanding role of Keytruda across new tumor
By IPP Bureau - October 11, 2025
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Dr. Jitendra Singh inaugurates 10th Annual "Cell and Gene Therapy" symposium
By IPP Bureau - October 11, 2025
Several technologies for hemoglobinopathies are being transferred to commercial partners
Botanic Healthcare unveils PeptiGlow and LipoLush for beauty and wellness
By IPP Bureau - October 11, 2025
PeptiGlow features premium-grade hydrolyzed collagen peptides that support skin elasticity and hydration
Allergan Aesthetics launches SkinMedica’s reimagined packaging
By IPP Bureau - October 11, 2025
SkinMedica redefines luxury skincare with reimagined packaging and new HA5 hydra collagen water burst moisturizer
Delhi High Court refuses to restrain Natco from manufacturing spinal muscular atrophy drug
By IPP Bureau - October 10, 2025
The Court dismissed Swiss drugmaker Roche’s plea for interim injunction
BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease
By IPP Bureau - October 10, 2025
Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants
Bayer and Kumquat initiate Phase I study with KRAS G12D inhibitor in patients with KRAS-mutated tumors
By IPP Bureau - October 10, 2025
First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors
AstraZeneca to increase investment in Virginia manufacturing facility to $4.5 billion
By IPP Bureau - October 10, 2025
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
